Berenberg Sees AstraZeneca’s HPP Drug as Potential Strensiq Franchise Expander

Berenberg analysts say AstraZeneca’s HPP treatment could replace and expand its existing $2 billion Strensiq franchise, with launch-related regulatory risk appearing surmountable amid unmet need.